These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35667841)

  • 1. Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models.
    Lélu K; Dubois C; Evlachev A; Crausaz M; Baldazza M; Kehrer N; Brandely R; Schlesinger Y; Silvestre N; Marchand JB; Bastien B; Leung-Theung-Long S; Unsinger J; Martin P; Inchauspé G
    J Immunol; 2022 Jul; 209(1):99-117. PubMed ID: 35667841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel virotherapy encoding human interleukin-7 improves
    Crausaz M; Monneret G; Conti F; Lukaszewicz AC; Marchand JB; Martin P; Inchauspé G; Venet F
    Front Immunol; 2022; 13():939899. PubMed ID: 36045686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous injection of a novel viral immunotherapy encoding human interleukin-7 in nonhuman primates is safe and increases absolute lymphocyte count.
    Coupet CA; Dubois C; Evlachev A; Kehrer N; Baldazza M; Hofman S; Vierboom M; Martin P; Inchauspe G
    Hum Vaccin Immunother; 2022 Nov; 18(6):2133914. PubMed ID: 36315906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia.
    Shindo Y; Fuchs AG; Davis CG; Eitas T; Unsinger J; Burnham CD; Green JM; Morre M; Bochicchio GV; Hotchkiss RS
    J Leukoc Biol; 2017 Feb; 101(2):543-554. PubMed ID: 27630218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
    García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
    PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-7 producing immunotherapy improves
    Marton C; Minaud A; Coupet CA; Chauvin M; Dhiab J; Vallet H; Boddaert J; Kehrer N; Bastien B; Inchauspe G; Barraud L; Sauce D
    Hum Vaccin Immunother; 2023 Aug; 19(2):2232247. PubMed ID: 37417353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
    García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
    J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
    Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.
    Inoue S; Unsinger J; Davis CG; Muenzer JT; Ferguson TA; Chang K; Osborne DF; Clark AT; Coopersmith CM; McDunn JE; Hotchkiss RS
    J Immunol; 2010 Feb; 184(3):1401-9. PubMed ID: 20026737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
    Tenesaca S; Vasquez M; Alvarez M; Otano I; Fernandez-Sendin M; Di Trani CA; Ardaiz N; Gomar C; Bella A; Aranda F; Medina-Echeverz J; Melero I; Berraondo P
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.
    Wolferstätter M; Schweneker M; Späth M; Lukassen S; Klingenberg M; Brinkmann K; Wielert U; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2014 Dec; 88(24):14396-411. PubMed ID: 25297997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
    Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sepsis leads to lasting changes in phenotype and function of naïve CD8 T cells.
    Berton RR; McGonagil PW; Jensen IJ; Ybarra TK; Bishop GA; Harty JT; Griffith TS; Badovinac VP
    PLoS Pathog; 2023 Oct; 19(10):e1011720. PubMed ID: 37824591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells.
    Zimmerling S; Waibler Z; Resch T; Sutter G; Schwantes A
    Virol J; 2013 Jan; 10():34. PubMed ID: 23356675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
    Claudepierre MC; Hortelano J; Schaedler E; Kleinpeter P; Geist M; Remy-Ziller C; Brandely R; Tosch C; Laruelle L; Jawhari A; Menguy T; Marchand JB; Romby P; Schultz P; Hartmann G; Rooke R; Bonnefoy JY; Preville X; Rittner K
    J Virol; 2014 May; 88(10):5242-55. PubMed ID: 24574403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of human dendritic cells by recombinant modified vaccinia virus Ankara vectors encoding survivin and IL-2 genes in vitro.
    Tao R; Li L; Huang W; Zheng L
    Hum Gene Ther; 2010 Jan; 21(1):98-108. PubMed ID: 19715401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
    Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
    PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
    García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
    PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.